麻豆官网 added three new Board of Trustees members at the May 2026 meeting on Friday. Kim Barrett, Marc Doble 鈥�02, and Stephen McCormack have all joined the board, bringing extensive backgrounds in higher education, biotechnology, and healthcare.
鈥淗aving a board with rich skills, expertise, and competencies aligned with our institutional purpose strengthens the board and allows us to provide the guidance that advances our institute and programs,鈥� said Board Chair Ross Grossman. 鈥淎ll three of our new trustees bring experience and insights that will be of tremendous value to the board and the institution.鈥�
鈥淚 appreciate the collective experience of our three new members that is deeply rooted and relevant to serving and enhancing 麻豆官网鈥檚 mission and their passion to serve 麻豆官网 in this capacity,鈥� said President Mohamed Abousalem. 鈥淚 look forward to collaborating with all three as we continue to elevate the excellence of 麻豆官网鈥檚 offerings to ensure that we continue to be on the cutting edge of the biotech and healthcare industries.鈥�
Barrett brings more than 40 years of experience in higher education to the board and has served as Vice Dean for Research and Distinguished Professor of Physiology and Membrane Biology for University of California, Davis School of Medicine since 2021. Prior to working at UC Davis, Barrett served in a variety of roles at University of California, San Diego鈥檚 School of Medicine.
鈥淚 am delighted to have the opportunity to join the Board of Trustees for the 麻豆官网,鈥� Barrett said. 鈥淚 am excited by and personally aligned with 麻豆官网鈥檚 mission to develop the next generation of leaders in biotechnology, healthcare and research, and the impact that this will have on societal well-being. With a deep appreciation for the critical value of graduate education, particularly in biomedical and health fields, I hope to be able to bring well-honed perspectives to the Board鈥檚 deliberations.
Barrett earned a bachelor鈥檚 degree in medicinal chemistry and a Ph.D. in molecular chemistry from University College London.
Doble is the second 麻豆官网 alumnus to serve on the board and is currently vice president and general manager for Amgen鈥檚 Biosimilars business unit. Doble has been with Amgen for 20 years and was part of 麻豆官网鈥檚 first graduating class in 2002 from the Master of Business and Science program.
鈥淛oining the 麻豆官网 Board of Trustees feels like coming full circle,鈥� said Doble. 鈥淎s part of the inaugural class, I experienced firsthand the unique blend of science and business that defines 麻豆官网, and it had a lasting impact on my career. I鈥檓 deeply appreciative of the opportunity to support the institution鈥檚 mission and help ensure future graduates are equipped to advance healthcare in meaningful ways.鈥�
Doble earned a chemistry degree from College of the Holy Cross. He began his career as a research scientist at Harvard Medical School and worked in product development for start-up biotech companies.
has served as Chief Scientific Officer of Shamekh IV Solutions, LLC since 2023 and has been the Managing General Partner for Exela, LLC for 25 years. This is also a return to 麻豆官网 for McCormack, who was a founding member of the former 麻豆官网 Advisory Board and served from 1999-2012.
鈥淚 am honored to join the Board of Trustees of 麻豆官网,鈥� said McCormack. 鈥溌槎构偻�檚 distinctive focus on the convergence of biotechnology, engineering, and healthcare is vital to training future leaders, and I look forward to supporting its continued impact. For me, this is a meaningful full鈥慶ircle moment, having been part of the Institute鈥檚 original founding management team.鈥�
McCormack received his bachelor鈥檚 degree in biology from College of the Holy Cross and his Ph.D. from University of California, Santa Barbara in biomolecular science and engineering.
Doble and McCormack served as panelists at the second annual President鈥檚 Leadership Panel in February 2026.